Table 4.
KEGG Pathway analysis for hippocampal proteins altered in BTBR mice compared to WT controls.
| KEGG pathway | C | E | O | R | P | H |
|---|---|---|---|---|---|---|
| Oxidative phosphorylation | 132 | 15 | 0.61 | 24.63 | 1.42E–15 | 365.6991 |
| Alzheimer's disease | 167 | 17 | 0.77 | 22.06 | 1.03E–16 | 352.6768 |
| Huntington's disease | 183 | 18 | 0.84 | 21.32 | 2.92E–17 | 352.518 |
| Parkinson's disease | 130 | 12 | 0.6 | 20 | 1.88E–11 | 214.5168 |
| Long–term potentiation | 70 | 8 | 0.32 | 24.77 | 1.74E–08 | 192.2016 |
| Gastric acid secretion | 74 | 8 | 0.34 | 23.43 | 2.34E–08 | 178.7893 |
| Collecting duct acid secretion | 27 | 4 | 0.12 | 32.11 | 4.01E–05 | 141.183 |
| Pyruvate metabolism | 40 | 5 | 0.18 | 27.09 | 7.57E–06 | 138.7253 |
| Metabolic pathways | 1130 | 37 | 5.21 | 7.1 | 5.38E–19 | 129.7114 |
| GnRH signaling pathway | 101 | 8 | 0.47 | 17.17 | 2.19E–07 | 114.3446 |
| Oocyte meiosis | 112 | 8 | 0.52 | 15.48 | 4.04E–07 | 98.97322 |
| Calcium signaling pathway | 177 | 10 | 0.82 | 12.24 | 1.14E–07 | 84.98348 |
| Vasopressin-regulated water reabsorption | 44 | 4 | 0.2 | 19.7 | 0.0002 | 72.86971 |
| Endocytosis | 201 | 10 | 0.93 | 10.78 | 3.03E–07 | 70.27005 |
| Citrate cycle (TCA cycle) | 30 | 3 | 0.14 | 21.67 | 0.001 | 65.01 |
| Butanoate metabolism | 30 | 3 | 0.14 | 21.67 | 0.001 | 65.01 |
| Propanoate metabolism | 32 | 3 | 0.15 | 20.32 | 0.001 | 60.96 |
| Alanine, aspartate and glutamate metabolism | 32 | 3 | 0.15 | 20.32 | 0.001 | 60.96 |
| Melanogenesis | 101 | 6 | 0.47 | 12.87 | 4.15E–05 | 56.39572 |
| Vibrio cholerae infection | 54 | 4 | 0.25 | 16.05 | 0.0004 | 54.53694 |
| Shigellosis | 61 | 4 | 0.28 | 14.21 | 0.0007 | 44.83116 |
| Wnt signaling pathway | 150 | 7 | 0.69 | 10.11 | 4.01E–05 | 44.45221 |
| Salivary secretion | 89 | 5 | 0.41 | 12.18 | 0.0003 | 42.90866 |
| Gap junction | 90 | 5 | 0.42 | 12.04 | 0.0003 | 42.41546 |
| Beta-Alanine metabolism | 22 | 2 | 0.1 | 19.7 | 0.0071 | 42.33021 |
| Glioma | 65 | 4 | 0.3 | 13.34 | 0.0007 | 42.08639 |
| Neurotrophin signaling pathway | 127 | 6 | 0.59 | 10.24 | 0.0001 | 40.96 |
| Valine, leucine and isoleucine degradation | 44 | 3 | 0.2 | 14.78 | 0.0023 | 38.99366 |
| Proteasome | 44 | 3 | 0.2 | 14.78 | 0.0023 | 38.99366 |
| Epithelial cell signaling in Helicobacter pylori infection | 68 | 4 | 0.31 | 12.75 | 0.0009 | 38.83341 |
| PPAR signaling pathway | 70 | 4 | 0.32 | 12.38 | 0.0009 | 37.70648 |
| Long-term depression | 70 | 4 | 0.32 | 12.38 | 0.0009 | 37.70648 |
| Bile secretion | 71 | 4 | 0.33 | 12.21 | 0.0009 | 37.1887 |
| Cardiac muscle contraction | 77 | 4 | 0.36 | 11.26 | 0.0012 | 32.88842 |
| Phosphatidylinositol signaling system | 78 | 4 | 0.36 | 11.11 | 0.0012 | 32.4503 |
| Pentose phosphate pathway | 27 | 2 | 0.12 | 16.05 | 0.0103 | 31.89396 |
| Amyotrophic lateral sclerosis (ALS) | 53 | 3 | 0.24 | 12.27 | 0.0036 | 29.98417 |
| ErbB signaling pathway | 87 | 4 | 0.4 | 9.96 | 0.0016 | 27.84696 |
| Inositol phosphate metabolism | 57 | 3 | 0.26 | 11.41 | 0.0043 | 27.00212 |
| Regulation of actin cytoskeleton | 213 | 7 | 0.98 | 7.12 | 0.0003 | 25.0829 |
| Glycolysis/Gluconeogenesis | 65 | 3 | 0.3 | 10 | 0.0057 | 22.44125 |
| Prion diseases | 35 | 2 | 0.16 | 12.38 | 0.0158 | 22.30063 |
| African trypanosomiasis | 35 | 2 | 0.16 | 12.38 | 0.0158 | 22.30063 |
| Pancreatic secretion | 101 | 4 | 0.47 | 8.58 | 0.0026 | 22.17953 |
| Adipocytokine signaling pathway | 68 | 3 | 0.31 | 9.56 | 0.0064 | 20.97292 |
| Bacterial invasion of epithelial cells | 70 | 3 | 0.32 | 9.29 | 0.0066 | 20.25644 |
| Renal cell carcinoma | 70 | 3 | 0.32 | 9.29 | 0.0066 | 20.25644 |
| Vascular smooth muscle contraction | 116 | 4 | 0.54 | 7.47 | 0.0039 | 17.99475 |
| Antigen processing and presentation | 76 | 3 | 0.35 | 8.55 | 0.0081 | 17.88245 |
| Purine metabolism | 162 | 5 | 0.75 | 6.69 | 0.0023 | 17.65004 |
| Protein processing in endoplasmic reticulum | 165 | 5 | 0.76 | 6.57 | 0.0023 | 17.33345 |
| Lysosome | 121 | 4 | 0.56 | 7.16 | 0.0044 | 16.87288 |
| Spliceosome | 127 | 4 | 0.59 | 6.83 | 0.005 | 15.71603 |
| Chemokine signaling pathway | 189 | 5 | 0.87 | 5.73 | 0.0036 | 14.00239 |
| Rheumatoid arthritis | 91 | 3 | 0.42 | 7.14 | 0.0127 | 13.53884 |
| Fc gamma R-mediated phagocytosis | 94 | 3 | 0.43 | 6.92 | 0.0136 | 12.91591 |
| Taste transduction | 52 | 2 | 0.24 | 8.34 | 0.0313 | 12.54716 |
| MAPK signaling pathway | 268 | 6 | 1.24 | 4.85 | 0.0032 | 12.10002 |
| Arginine and proline metabolism | 54 | 2 | 0.25 | 8.03 | 0.0325 | 11.94958 |
| Pathogenic Escherichia coli infection | 56 | 2 | 0.26 | 7.74 | 0.0342 | 11.34664 |
| Chagas disease (American trypanosomiasis) | 104 | 3 | 0.48 | 6.25 | 0.017 | 11.05969 |
| Amoebiasis | 106 | 3 | 0.49 | 6.13 | 0.0177 | 10.73992 |
| Toxoplasmosis | 132 | 3 | 0.61 | 4.93 | 0.0309 | 7.444505 |
| Natural killer cell mediated cytotoxicity | 136 | 3 | 0.63 | 4.78 | 0.0324 | 7.119595 |
| Phagosome | 153 | 3 | 0.71 | 4.25 | 0.0416 | 5.868853 |
KEGG signaling pathway annotation of the hippocampal proteins possessing BTBR:WT iTRAQ expression ratios < 1.2 or < 0.8 was created using WebGestalt. Each KEGG pathway significantly populated (p < 0.05) by at least two independent proteins are depicted. For each populated KEGG pathway the number of total proteins in the curated KEGG pathway (C), the number of observed experimental proteins in the KEGG pathway (O), the expected number of proteins in the pathway based on whole-genome background frequency (E), the KEGG pathway enrichment factor (R), the KEGG pathway enrichment probability (P) and the hybrid score (R * −log10 P) are indicated (H).